To assess the ability of these DNA vaccine constructs expressing LS malaria antigens to protect against malaria, groups of 7–8 mice were immunized 4 times at 3 week intervals with combinations of constructs (EXP1_PFN alone, EXP2 and ICP, TMP21 and UIS3, and all constructs together) with and without the molecular adjuvant pIL-33, and then challenged 9 weeks later with intravenous delivery of 250 infectious P. yoelii sporozoites. Here, CSE1L is linked to malaria.